CBD has been touted for a wide variety of health issues, but the strongest scientific evidence is based on its effectiveness in treating some of the most severe childhood epileptic syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS). These conditions typically do not respond to anticonvulsant medications. CBD also has a therapeutic effect, making it able to help with pain and inflammation. People with chronic pain have used it as an alternative to traditional medication, with many reporting feeling much better after using CBD oil.
It is scientifically proven to help treat headaches, insomnia, mental health disorders, arthritis and other chronic syndromes. For centuries, people have used marijuana for medical purposes to treat their chronic pain. Nowadays, medical marijuana is associated with CBD, which appears to be legitimate. This approval has encouraged the cannabinoid research community, which has long recognized the medicinal potential of CBD but faces skepticism and regulatory restrictions on the road to the clinic.I researched and discovered that other families and children, such as Charlotte Figi, reported having been successful with CBD, and I knew it was something that needed to be investigated.
Devinsky notes that many of his patients with epilepsy have also been diagnosed with autism spectrum disorder, and is participating in two clinical trials that aim to assess whether CBD can significantly reduce irritability and anxiety in people with autism.What they didn't know was that by increasing the THC content, they were drastically reducing the CBD content. Some users have praised CBD for curing pain, anxiety, insomnia, depression or seizures, and advertisers promote it as a supplement that can treat all of these conditions and combat aging and chronic diseases.The presence of THC and other cannabinoids in CBD-rich products may affect the results of this study. While structurally similar to Δ9-tetrahydrocannabinol (THC), CBD does not cause intoxication or euphoria (Russo 201) and has demonstrated considerable tolerability in humans with a low potential for abuse (Chesney et al.). This is one of several reasons why researchers warn against self-medication with CBD products aimed at consumers.However, synthetic CBD still falls under the Schedule 1 classification in the United States, creating additional economic and bureaucratic obstacles to clinical trials.This study on CBD-rich products demonstrates the potential of real-world evidence (RWE) to advance research and practice guidelines for medical cannabis, especially in a world where CBD consumption is increasing exponentially but scientific data are limited.
There is a probable placebo effect; however, there were no differences in initial doses of CBD between severity groups. The future of CBD seems full of potential, but today there are more questions than answers. For example, while 300 milligrams of CBD can reduce a person's anxiety, the same person may not get any relief with a dose of 100 or 900 milligrams.Zuardi's group investigated the efficacy, tolerability and safety of CBD in psychotic patients with Parkinson's disease (PD) using a 4-week open-label pilot study. Some of the best research on the therapeutic effects of CBD comes from the treatment of childhood epilepsy (thanks to the Figi family), schizophrenia, lack of sleep and anxiety disorders.It revealed that CBD-rich treatments have a beneficial impact on patients with self-reported moderate or severe symptoms of pain, anxiety or depression and on general well-being, but not on patients with mild symptoms.
